Feasibility study of neoadjuvant mFOLFOX6 plus cetuximab in patients with resectable liver limited metastases from colorectal cancer harboring KRAS wild type
Phase 2
- Conditions
- Metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000007545
- Lead Sponsor
- ational Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval (2)Symptomatic brain metastases (3)Severe infectious disease (4)Interstitial lung disease or pulmonary fibrosis (5)Comorbidity or history of heart failure (6)Sensory alteration or paresthesia interfering with function (7)Severe comorbidity (renal failure, liver failure, hypertension, etc) (8)History of severe allergy (9)Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment completion rate
- Secondary Outcome Measures
Name Time Method Safety(CTCAE ver4.0), RR, Liver resectability, R0 rate, Postoperative complications, Explore the appropriate treatment duration from ICG (after 4 and 6 course) and CT